Peptidomimetic ligands for cellular receptors and ion channels
    1.
    发明授权
    Peptidomimetic ligands for cellular receptors and ion channels 有权
    肽模拟配体的细胞受体和离子通道

    公开(公告)号:US07115664B2

    公开(公告)日:2006-10-03

    申请号:US10203279

    申请日:2001-02-27

    摘要: One aspect of the present invention relates to novel peptidomimetic compounds. A second aspect of the present invention relates to the use of the novel peptidomimetic compounds as ligands—agonists or antagonists—for various cellular receptors, e.g., G-protein-coupled receptors and opioid receptors, and various cellular ion channels, e.g., sodium and calcium. In certain embodiments, compounds of the present invention preferentially or selectively inhibit sodium or calcium ion channels. In certain embodiments, compounds of the present invention preferentially or selectively agonize or antagonize $gm opioid receptors. In certain embodiments, compounds of the present invention preferentially or selectively inhibit sodium or calcium ion channels and agonize or antagonize $gm-opioid receptors

    摘要翻译: 本发明的一个方面涉及新的拟肽化合物。 本发明的第二方面涉及新型拟肽化合物作为配体 - 激动剂或拮抗剂 - 用于各种细胞受体(例如G-蛋白偶联受体和阿片受体)和各种细胞离子通道(例如钠和 钙。 在某些实施方案中,本发明的化合物优选或选择性地抑制钠离子或钙离子通道。 在某些实施方案中,本发明的化合物优选地或选择性地激动或拮抗$ g阿片受体。 在某些实施方案中,本发明的化合物优先或选择性地抑制钠离子通道或钙离子通道,并激动或拮抗$ gm-阿片受体

    Potentiation of MC4 receptor activity
    7.
    发明申请
    Potentiation of MC4 receptor activity 审中-公开
    MC4受体活性的增强

    公开(公告)号:US20080027072A1

    公开(公告)日:2008-01-31

    申请号:US11788748

    申请日:2007-04-19

    摘要: The present invention provides methods of treating obesity, eating disorders, and sexual dysfunction. The methods comprise administering to a mammalian host suffering from obesity, an eating disorder, or sexual dysfunction an effective dose of a compound of the invention. Also provided are methods of potentiating the effect of an MC4 receptor agonist in a mammalian host. In some cases the methods comprise administering to the host a compound that lowers the EC50 of the agonist. In other cases the methods comprise administering to the host a compound that increases the maximum effect of the agonist.

    摘要翻译: 本发明提供治疗肥胖,进食障碍和性功能障碍的方法。 所述方法包括向患有肥胖,进食障碍或性功能障碍的哺乳动物宿主施用有效剂量的本发明化合物。 还提供了增强哺乳动物宿主中MC4受体激动剂的作用的方法。 在一些情况下,所述方法包括向宿主施用降低激动剂的EC 50的化合物。 在其他情况下,所述方法包括向宿主施用增加激动剂的最大效果的化合物。

    Peptidomimetic ligands for cellular receptors and ion channels
    8.
    发明申请
    Peptidomimetic ligands for cellular receptors and ion channels 有权
    肽模拟配体的细胞受体和离子通道

    公开(公告)号:US20070093522A1

    公开(公告)日:2007-04-26

    申请号:US11512056

    申请日:2006-08-29

    摘要: One aspect of the present invention relates to novel peptidomometic compounds. A second aspect of the present invention relates to the use of the novel peptidomimetic compounds as ligands—agonists or antagonists—for various cellular receptors, e.g., G-protein-coupled receptors and opioid receptors, and various cellular ion channels, e.g., sodium and calcium. In certain embodiments, compounds of the present invention preferentially or selectively inhibit sodium or calcium ion channels. In certain embodiments, compounds of the present invention preferentially or selectively agonize or antagonize μ opioid receptors. In certain embodiments, compounds of the present invention preferentially or selectively inhibit sodium or calcium ion channels and agonize or antagonize μ-opioid receptors.

    摘要翻译: 本发明的一个方面涉及新颖的肽模拟化合物。 本发明的第二方面涉及新型拟肽化合物作为配体 - 激动剂或拮抗剂用于各种细胞受体,例如G-蛋白偶联受体和阿片受体,以及各种细胞离子通道(例如钠和 钙。 在某些实施方案中,本发明的化合物优选或选择性地抑制钠离子或钙离子通道。 在某些实施方案中,本发明的化合物优选地或选择性地激动或拮抗μ阿片受体。 在某些实施方案中,本发明的化合物优选地或选择性地抑制钠离子通道或钙离子通道并且激动或拮抗μ-阿片受体。

    Spirocyclic ligands for sigma receptors, and libraries and methods of use thereof
    9.
    发明申请
    Spirocyclic ligands for sigma receptors, and libraries and methods of use thereof 有权
    用于σ受体的螺环配体,以及文库及其使用方法

    公开(公告)号:US20050038011A1

    公开(公告)日:2005-02-17

    申请号:US10890408

    申请日:2004-07-13

    CPC分类号: C07D471/10 C40B40/00

    摘要: One aspect of the present invention relates to spirocyclic compounds. Another aspect of the present invention relates to the use of the spirocyclic compounds as ligands for mammalian G-protein-coupled receptors or sigma receptors. The present invention also relates to methods of modulating the activity of a G-protein-coupled receptor or a sigma receptor in a mammal using the spirocyclic compounds of the present invention. The present invention also relates to methods of treating various diseases in a mammal using the spirocyclic compounds of the present invention.

    摘要翻译: 本发明的一个方面涉及螺环化合物。 本发明的另一方面涉及螺环化合物作为哺乳动物G蛋白偶联受体或σ受体的配体的用途。 本发明还涉及使用本发明的螺环化合物调节哺乳动物中G蛋白偶联受体或σ受体的活性的方法。 本发明还涉及使用本发明的螺环化合物治疗哺乳动物中各种疾病的方法。